Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
After May 2012, yet another gas price revision was announced by industrial gas producer and supplier, Praxair Inc. ( PX - Analyst Report ) . The price revision will apply to all the divisions and subsidiaries of the company, effective January 1, 2013.
Prices of nitrogen, oxygen and carbon dioxide have been increased up to 15% while argon and hydrogen prices have been raised to 20%. Facility fees or monthly bulk product charges and cylinder rental rates have gone up by 15% while prices for hardwoods have escalated by 15% and helium up to 30%.
These revised prices will apply to the bulk and packaged industrial, electronics, specialty and medical gas customers in the United States, Canada and Puerto Rico. Higher raw material costs and maintenance of supply/demand balance were the prime catalysts driving this revision.
It is also worth mentioning that recently, Praxair’s prime competitor, Air Products & Chemicals Inc. ( APD - Analyst Report ) announced increases in specialty gas and process materials that are supplied by its Electronics business. The revised prices will be effective from January 1, 2013.
Long-term prospects look promising for Praxair with increasing application areas for industrial gases. Chemical processing, petroleum refining, metal production, fabricating, electronics and health care industries are widely using these gases. By 2015, the company targets to achieve annual organic sales growth of 8%-12%; operating profit growth of 10%-15%, and earnings growth of 12%-18%.
The current Zacks Consensus Estimate for the fourth quarter stands at $1.38, representing a year-over-year increase of 1.76%. Estimates for years 2012 and 2013 are $5.57 and $6.18, reflecting annual growth of 2.5% and 11.1%, respectively.
We currently maintain a Neutral recommendation on Praxair. The stock also currently bears a Zacks #4 Rank, implying a short-term Sell rating.
Read the full Analyst Report on PX
Read the full Analyst Report on APD